How We're Keeping You Safe | What Patients & Families Need to Know

A photo of Sonata Jodele.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Professor, UC Department of Pediatrics



Board Certified

My Biography & Research


Dr. Jodele is an international expert in all aspects of transplant- associated thrombotic microangiopathy (TMA), clinical and research. She made major contributions to the field by linking TMA pathophysiology to the complement pathway, demonstrating the relationship of the disease to specific clinical and genetic factors, and then establishing a new paradigm for therapy with inhibition of the complement pathway. She is a leader in ongoing research efforts to develop new and better therapies for TMA. Due to her extensive experience in the care of complex transplant patients Dr. Jodele leads multi-disciplinary international collaborative groups and research projects around the world with clinicians and scientists from Germany, Switzerland, Italy and Japan.

Dr. Jodele serves as a clinical consultant for the physicians throughout the world regarding care of complex patients with this disorder. Dr. Jodele led the first prospective TMA biomarker and genetic predisposition studies. These studies resulted in practical applications to clinical care and also comprehensive diagnostic laboratory panels that are now offered for national and international patients. She also proposed new diagnostic algorithms and risk stratification criteria for TMA to guide timely initiation of therapy.

Dr. Jodele piloted novel complement blocking therapeutic agents for HSCT recipients with severe TMA and described unique drug pharmacokinetics in this patient population. This work led to the opening of first prospective early intervention clinical study at four major pediatric centers in USA using eculizumab for stem cell transplant recipients with high risk TMA. Dr. Jodele’s research is supported by the NIH, as well as institutional and industry sponsored grants.

Clinical Interests

Bone marrow transplantation and cellular therapies

Research Interests

Thrombotic microangiopathies; organ toxicity prevention in transplant patients

Academic Affiliation

Professor, UC Department of Pediatrics


Bone Marrow Transplantation BMT, Cancer and Blood Diseases, Bone Marrow Transplantation

My Education

MD: Vilnius University School of Medicine, Vilnius, Lithuania, 1988-1994.

Residency: Pediatrics, SUNY Health Science Center at Brooklyn, Brooklyn, NY, 1998-2001.

Fellowship: Pediatric Hematology/Oncology, Children's Hospital Los Angeles and Saban Research Institute, Keck School of Medicine University of Southern California, Los Angeles, CA, 2001-2004.

Certifications: Pediatrics, 2001; Pediatric Hematology / Oncology, 2004.

Licenses: California, 2001-present; Ohio, 2004-present.

My Publications

Selected Publication

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Jodele, S; Dandoy, CE; Lane, A; Laskin, BL; Laskin, B; Teusink-Cross, A; Myers, KC; Wallace, G; Nelson, AS; Nelson, A; et al. Blood. 2020; 26:S138-S138.

Interferon-complement loop in transplant-associated thrombotic microangiopathy. Jodele, S; Medvedovic, M; Luebbering, N; Chen, J; Dandoy, CE; Laskin, BL; Davies, SM. Blood Advances. 2020; 4:1166-1177.

High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Jodele, S; Dandoy, CE; Myers, K; Wallace, G; Lane, A; Teusink-Cross, A; Weiss, B; Davies, SM. Bone Marrow Transplantation. 2018; 53:1311-1318.

Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination. Jodele, S; Dandoy, CE; Danziger-Isakov, L; Myers, KC; El-Bietar, J; Nelson, A; Wallace, G; Teusink-Cross, A; Davies, SM. Biology of Blood and Marrow Transplantation. 2016; 22:1337-1340.

New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Jodele, S; Dandoy, CE; Myers, KC; El-Bietar, J; Nelson, A; Wallace, G; Laskin, BL. Transfusion and Apheresis Science. 2016; 54:181-190.

The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Jodele, S; Zhang, K; Zou, F; Laskin, B; Dandoy, CE; Myers, KC; Lane, A; Meller, J; Medvedovic, M; Chen, J; et al. Blood. 2016; 127:989-996.

Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Jodele, S; Fukuda, T; Mizuno, K; Vinks, AA; Laskin, BL; Goebel, J; Dixon, BP; Chima, RS; Hirsch, R; Teusink, A; et al. Biology of Blood and Marrow Transplantation. 2016; 22:307-315.

Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Jodele, S; Davies, SM; Lane, A; Khoury, J; Dandoy, C; Goebel, J; Myers, K; Grimley, M; Bleesing, J; El-Bietar, J; et al. Blood. 2014; 124:645-653.

Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Jodele, S; Fukuda, T; Vinks, A; Mizuno, K; Laskin, BL; Goebel, J; Dixon, BP; Teusink, A; Pluthero, FG; Lu, L; et al. Biology of Blood and Marrow Transplantation. 2014; 20:518-525.

Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Jodele, S; Licht, C; Goebel, J; Dixon, BP; Zhang, K; Sivakumaran, TA; Davies, SM; Pluthero, FG; Lu, L; Laskin, BL. Blood. 2013; 122:2003-2007.